Goldstein Advisors LLC Cuts Stake in Pfizer Inc. (NYSE:PFE)

Goldstein Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 5.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,437 shares of the biopharmaceutical company’s stock after selling 629 shares during the period. Goldstein Advisors LLC’s holdings in Pfizer were worth $277,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Wescott Financial Advisory Group LLC purchased a new position in shares of Pfizer in the second quarter valued at $224,000. Fred Alger Management LLC grew its stake in shares of Pfizer by 6.6% in the 2nd quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock worth $2,675,000 after buying an additional 5,932 shares in the last quarter. Point72 Europe London LLP bought a new stake in shares of Pfizer in the 2nd quarter worth about $3,698,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $3,452,000. Finally, Caxton Associates LP bought a new position in shares of Pfizer in the 2nd quarter valued at about $738,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.01 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average price is $26.07 and its 200-day moving average price is $27.96. The firm has a market cap of $147.40 billion, a P/E ratio of 35.15, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PFE shares. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.